<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:39:23Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6738104" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6738104</identifier>
        <datestamp>2020-08-13</datestamp>
        <setSpec>brjcancer</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
              <journal-id journal-id-type="iso-abbrev">Br J Cancer</journal-id>
              <journal-title-group>
                <journal-title>British Journal of Cancer</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0007-0920</issn>
              <issn pub-type="epub">1532-1827</issn>
              <publisher>
                <publisher-name>Nature Publishing Group UK</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6738104</article-id>
              <article-id pub-id-type="pmcid">PMC6738104</article-id>
              <article-id pub-id-type="pmc-uid">6738104</article-id>
              <article-id pub-id-type="pmid">31406299</article-id>
              <article-id pub-id-type="pmid">31406299</article-id>
              <article-id pub-id-type="publisher-id">548</article-id>
              <article-id pub-id-type="doi">10.1038/s41416-019-0548-9</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Korphaisarn</surname>
                    <given-names>Krittiya</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Morris</surname>
                    <given-names>Van</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Davis</surname>
                    <given-names>Jenifer S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Overman</surname>
                    <given-names>Michael J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fogelman</surname>
                    <given-names>David R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kee</surname>
                    <given-names>Bryan K.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dasari</surname>
                    <given-names>Arvind</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Raghav</surname>
                    <given-names>Kanwal P. S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shureiqi</surname>
                    <given-names>Imad</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Trupti</surname>
                    <given-names>Metha</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wolff</surname>
                    <given-names>Robert A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Eng</surname>
                    <given-names>Cathy</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Menter</surname>
                    <given-names>David G.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hamilton</surname>
                    <given-names>Stanley</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Kopetz</surname>
                    <given-names>Scott</given-names>
                  </name>
                  <address>
                    <phone>+(713) 792-2828</phone>
                    <email>skopetz@mdanderson.org</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution>Department of Gastrointestinal Medical Oncology, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, TX USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution>Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, </institution><institution>Mahidol University, </institution></institution-wrap>Bangkok, Thailand </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution>Department of Epidemiology, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, TX USA </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution>Department of Pathology, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, TX USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>13</day>
                <month>8</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <day>10</day>
                <month>9</month>
                <year>2019</year>
              </pub-date>
              <volume>121</volume>
              <issue>6</issue>
              <fpage>505</fpage>
              <lpage>510</lpage>
              <history>
                <date date-type="received">
                  <day>11</day>
                  <month>4</month>
                  <year>2019</year>
                </date>
                <date date-type="rev-recd">
                  <day>16</day>
                  <month>7</month>
                  <year>2019</year>
                </date>
                <date date-type="accepted">
                  <day>24</day>
                  <month>7</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s), under exclusive licence to Cancer Research UK 2019</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Background</title>
                  <p id="Par1">Signet ring cell carcinoma (SRCC) is a rare subtype of colorectal cancer (CRC). The aim of this study was to characterise the genomic alterations and outcomes of SRCC.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p id="Par2">Medical records of metastatic CRC (mCRC) patients whose tumours were evaluated by NGS analysis were reviewed. SC-mCRC were classified into two groups: SRCC (&gt;50% signet ring cells) and adenocarcinoma (AC) with SC component (≤50% signet ring cells).</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p id="Par3">Six hundred and sixty-five mCRC patients were included. Of the 93 mCRC cases with SC features, 63 had slides for review. Of those 63 cases, 35 were confirmed SRCC, and 28 were AC with SC component. Compared with AC group, <italic>KRAS and PIK3CA</italic> mutations (mts) were found in only 11% (OR: 0.13) and 3% (OR: 0.15) of SRCC cases, respectively. In contrast to the 44% rate of <italic>APC</italic> mts in AC group, only 3% of SRCC patients had <italic>APC</italic> mts (OR = 0.04).</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p id="Par4">SRCC has distinct molecular features, including low rates of <italic>KRAS</italic>, <italic>PIK3CA</italic> and <italic>APC</italic> mts. Further study to identify activation pathways and potential therapeutic targets are needed.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="npg-subject">
                <title>Subject terms</title>
                <kwd>Colorectal cancer</kwd>
                <kwd>Cancer genomics</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>the National Institutes of Health through Cancer Center Support Grant P30CA016672 and R01CA187238</institution>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© Cancer Research UK 2019</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Background</title>
              <p id="Par5">Colorectal cancer (CRC) is the third most commonly diagnosed cancer, and the fourth leading cause of cancer death in the world.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> CRC has a variety of histologies, including adenocarcinoma (AC), and rare histologies, such as adenosquamous carcinomas, squamous cell carcinomas, neuroendocrine carcinomas, spindle cell carcinomas and undifferentiated carcinomas.<sup><xref ref-type="bibr" rid="CR2">2</xref></sup> Signet ring cell colorectal cancer (SRCC) is a rare subtype of colorectal adenocarcinoma that accounts for 1–2.4% of all CRC.<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref></sup> The histology of SRCC is distinguished from typical adenocarcinoma by an excess amount of intracellular mucin that displaces the nucleus, which results in the formation of signet ring cell (SC) features. SRCC is defined by a greater than 50% presence of signet ring cells, while cases with less than or equal to 50% presence of signet ring cells are noted to have signet ring features without a formal SRCC designation.<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> In the previous studies, SRCC has been associated with younger age, advanced tumour stage at presentation and lymph node metastasis,<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR6">6</xref>–<xref ref-type="bibr" rid="CR8">8</xref></sup> and SRCC has significantly poorer prognosis compared to that of adenocarcinomas.<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR14">14</xref></sup> Several studies have suggested a higher rate of microsatellite instability and <italic>BRAF</italic> gene mutation in SRCC.<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR17">17</xref></sup> However, the sample sizes in those studies were generally small, and most evaluated only single gene mutation. A more extensive clinical and molecular characterisation of this subset is needed. Accordingly, the aim of this study was to characterise the genomic alterations, clinicopathological characteristics and outcomes of SRCC.</p>
            </sec>
            <sec id="Sec2">
              <title>Methods</title>
              <p id="Par6">This single centre, retrospective cohort study evaluated patients with metastatic CRC (mCRC) who were enrolled in the Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC) program at The University of Texas MD Anderson Cancer Center (UTMDACC) between 13 February 2009 and 18 November 2015, as described previously.<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> Additional mCRC cases having signet ring cell features between 1 March 1994 and 31 August 2015 were extracted from the tumour registry at UTMDACC. The protocol for this study was approved by The University of Texas MD Anderson Cancer Center Institutional Review Board. All patients provided written informed consent prior to sequencing of their tumours according to the institutional guideline. The primary objective of this study was to determine the molecular characteristics of SRCC. The secondary objectives were to identify significant associations between SRCC and various clinicopathologic characteristics, and to evaluate their prognostic impact on overall survival (OS).</p>
              <sec id="Sec3">
                <title>Pathologic evaluation</title>
                <p id="Par7">Slides from patients whose pathology report documented the presence of signet ring cell histology were obtained and reviewed to confirm the percentage of signet ring cells. Haematoxylin and eosin-stained slides of the tumours were reviewed by an experienced gastrointestinal pathologist (SH). Tumours were classified according to the proportion of signet ring cells, with ≥50% defining SRCC, and ≤50% defining AC with SC component.</p>
              </sec>
              <sec id="Sec4">
                <title>Clinical characteristics</title>
                <p id="Par8">As described previously,<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> demographic and clinical information, including age, gender, race, primary tumour site, date of diagnosis with stage IV disease, date of last follow-up and date of death, were collected from a review of patient medical records. Right-sided colon cancer was defined as cancer in the region from the cecum to the splenic flexure, while left-sided colon cancer was defined as cancer in the region from the descending colon through the sigmoid colon, and the rectum was considered a separate site. Staging was performed using the American Joint Committee on Cancer/Union for International Cancer Control TMN staging system (version 7, 2010). OS was defined as the interval between the date of diagnosis of metastatic disease and the date of death from any cause. Patients alive at the time of analysis were censored at their last known follow-up date</p>
              </sec>
              <sec id="Sec5">
                <title>Molecular characterisation</title>
                <p id="Par9">As described previously,<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> DNA was extracted from paraffin-embedded formalin-fixed tumour tissue. Samples were evaluated using a next-generation sequencing platform with 46- or 50-gene panels for the detection of frequently reported point mutations in human malignancies. Complete details of exon and codon coverage in all genes were previously reported.<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> DNA testing was performed in a Clinical Laboratory Improvement Amendments-certified molecular diagnostics laboratory that determined the effective lower limit of detection (analytical sensitivity) for single nucleotide variations to be in the range of 5% (one mutant allele in the background of nineteen wild-type alleles) to 10% (one mutant allele in the background of nine wild-type alleles). Details relating to the codons and exons tested are shown in Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>.</p>
              </sec>
              <sec id="Sec6">
                <title>Determine of MMR status</title>
                <p id="Par10">MMR status was determined by analysis of MMR protein expression by immunohistochemistry (IHC) or microsatellite instability (MSI) testing. Deficient mismatch repair (dMMR) was defined as the presence of either high-level MSI (MSI-H) or loss of MMR protein expression. Proficient mismatch repair (pMMR) was defined as the presence of either microsatellite stable (MSS)/low-level MSI (MSI-L) or the presence of normal MMR protein expression. Complete details of IHC analysis of MMR expression and microsatellite instability (MSI) testing were previously published.<sup><xref ref-type="bibr" rid="CR18">18</xref></sup></p>
              </sec>
              <sec id="Sec7">
                <title>CpG Island Methylation Phenotype (CIMP) panel methylation analysis</title>
                <p id="Par11">As described previously,<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> DNA extracted from formalin-fixed, paraffin-embedded tissue was treated with bisulfite to convert unmethylated cytosine to uracil. PCR amplification of unmethylated and methylated MINT1, MINT2 and MINT31 loci, and promoter sequences of p14, p16 and hMLH1 genes was performed, and methylation status was assessed by pyrosequencing. The tumour was considered CIMP High if at least 40% of the markers tested show methylation, and CIMP Low if &lt;40% of the tested markers show methylation.</p>
              </sec>
              <sec id="Sec8">
                <title>Statistical analysis</title>
                <p id="Par12">Patient characteristics were compared using descriptive statistics. Pearson’s Chi-square test or Fisher’s exact test was applied to evaluate associations between SRCC and clinicopathological variables, and binary logistic regression was used to calculate odds ratios. Survival was analysed using the Kaplan–Meier method, and comparisons between groups were made using the log-rank test. Cox proportional hazard models were used to estimate the combined influence of clinical and pathologic feature on survival. Median follow-up time was calculated using the reverse Kaplan–Meier method. A two-sided level of significance of 0.05 was applied for all statistical tests. Calculations were performed using SPSS Statistics version 23.0 software (IBM Corp., Armonk, NY, USA).</p>
              </sec>
            </sec>
            <sec id="Sec9" sec-type="results">
              <title>Results</title>
              <p id="Par13">Six hundred and sixty-five mCRC patients with NGS molecular data were included. Of the 93 mCRC cases with SC features, 63 had available slides for confirmatory review. Of those 63 cases, 35 were confirmed SRCC, and 28 were considered AC with SC component (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>).</p>
              <p id="Par14">The frequency of confirmed SRCC and AC with SC components in the entire cohort was 5.5% (35/635) and 4.4% (28/635), respectively. However, if analysis only the data form ATTACC database, 1.3% (8/604) and 2.3% (14/604) were classified as SRCC and AC with SC components, respectively. The median age was 55 years (range: 15–85), the ratio of males to females was 1.29, and the majority of patients were Caucasian. Patient and tumour characteristics are shown in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Demographic and clinical characteristics of the study population, n (%)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th><italic>n</italic></th><th>%</th></tr></thead><tbody><tr><td>No. of patients</td><td>665</td><td>100</td></tr><tr><td>Age (years), median (range)</td><td>55 (15–85)</td><td/></tr><tr><td>Gender</td><td/><td/></tr><tr><td> Female</td><td>291</td><td>43.8</td></tr><tr><td> Male</td><td>374</td><td>56.2</td></tr><tr><td>Age</td><td/><td/></tr><tr><td> 15–39</td><td>70</td><td>10.5</td></tr><tr><td> 40–49</td><td>153</td><td>23.0</td></tr><tr><td> ≥50</td><td>442</td><td>66.5</td></tr><tr><td>Site</td><td/><td/></tr><tr><td> Right-sided</td><td>243</td><td>36.5</td></tr><tr><td> Left-sided</td><td>274</td><td>41.2</td></tr><tr><td> Rectum</td><td>142</td><td>21.4</td></tr><tr><td> No data</td><td>6</td><td>0.9</td></tr><tr><td>Race</td><td/><td/></tr><tr><td> Asian</td><td>34</td><td>5.1</td></tr><tr><td> Black</td><td>60</td><td>9.0</td></tr><tr><td> Hispanic</td><td>61</td><td>9.2</td></tr><tr><td> White</td><td>503</td><td>75.6</td></tr><tr><td> No data</td><td>7</td><td>1.1</td></tr><tr><td>Histology</td><td/><td/></tr><tr><td> Adenocarcinama (AC)</td><td>572</td><td>86.0</td></tr><tr><td> Signet ring cell features (<italic>n</italic> = 93)</td><td/><td/></tr><tr><td>  Confirmed SRCC</td><td>35</td><td>5.3</td></tr><tr><td>  AC with SC</td><td>28</td><td>4.2</td></tr><tr><td>  No slide reviewed</td><td>30</td><td>4.5</td></tr><tr><td>Differentiated</td><td/><td/></tr><tr><td> Well</td><td>1</td><td>0.2</td></tr><tr><td> Moderately</td><td>449</td><td>67.5</td></tr><tr><td> Poorly</td><td>209</td><td>31.4</td></tr><tr><td> Not available</td><td>6</td><td>0.9</td></tr><tr><td>Liver metastasis</td><td/><td/></tr><tr><td> No</td><td>201</td><td>30.2</td></tr><tr><td> Yes</td><td>464</td><td>69.8</td></tr><tr><td>Lung metastasis</td><td/><td/></tr><tr><td> No</td><td>262</td><td>39.4</td></tr><tr><td> Yes</td><td>403</td><td>60.6</td></tr><tr><td>Peritoneal metastasis</td><td/><td/></tr><tr><td> No</td><td>400</td><td>60.2</td></tr><tr><td> Yes</td><td>265</td><td>39.8</td></tr></tbody></table><table-wrap-foot><p><italic>SRCC</italic> signet ring cell colorectal cancer, <italic>AC with SC</italic> adenocarcinoma with signet ring cell component, <italic>AC</italic> adenocarcinoma</p></table-wrap-foot></table-wrap></p>
              <sec id="Sec10">
                <title>Clinicopathologic features</title>
                <p id="Par15">Compared with the AC group, SRCC was significantly more commonly found in patients with right-sided tumour (odds ratio [OR]: 3.4, <italic>p</italic> = 0.001), poorly differentiated tumour (<italic>p</italic> &lt; 0.001) or peritoneal metastasis (OR: 9.8, <italic>p</italic> &lt; 0.001). In contrast, SRCC was significantly less frequently found in cases with liver metastasis (OR: 0.1, <italic>p</italic> &lt; 0.001) or lung metastasis (OR: 0.1, <italic>p</italic> &lt; 0.001). Patients with SRCC were 2.4-fold more likely to be diagnosed before the age of 40 (<italic>p</italic> = 0.04) (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Clinical characteristics of study population by histology (only reviewed slide cases; <italic>n</italic> = 635)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th colspan="6">Histology</th><th rowspan="2"><italic>p</italic>-value*</th></tr><tr><th>SRCC</th><th>%</th><th>AC with SC</th><th>%</th><th>AC</th><th>%</th></tr></thead><tbody><tr><td>Gender</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td> Female</td><td>18</td><td>51.4</td><td>14</td><td>50.0</td><td>245</td><td>42.8</td><td rowspan="2">0.32</td></tr><tr><td> Male</td><td>17</td><td>48.6</td><td>14</td><td>50.0</td><td>327</td><td>57.2</td></tr><tr><td>Age</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td> 15–39</td><td>7</td><td>20.0</td><td>2</td><td>7.1</td><td>53</td><td>9.3</td><td rowspan="3">0.10</td></tr><tr><td> 40–49</td><td>9</td><td>25.7</td><td>6</td><td>21.4</td><td>136</td><td>23.8</td></tr><tr><td> ≥50</td><td>19</td><td>54.3</td><td>20</td><td>71.4</td><td>383</td><td>67.0</td></tr><tr><td>Site (<italic>n</italic> = 602)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td> Right-sided</td><td>22</td><td>62.9</td><td>12</td><td>42.9</td><td>189</td><td>33.3</td><td rowspan="2"><bold>0.001</bold></td></tr><tr><td> Left-sided</td><td>13</td><td>37.1</td><td>16</td><td>57.1</td><td>378</td><td>66.7</td></tr><tr><td>Race (<italic>n</italic> = 602)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>  Asian</td><td>1</td><td>2.9</td><td>0</td><td>0.0</td><td>32</td><td>5.6</td><td rowspan="4">0.43</td></tr><tr><td>  Black</td><td>4</td><td>11.8</td><td>2</td><td>7.1</td><td>53</td><td>9.3</td></tr><tr><td>  Hispanic</td><td>2</td><td>5.9</td><td>2</td><td>7.1</td><td>53</td><td>9.3</td></tr><tr><td>  White</td><td>27</td><td>79.4</td><td>24</td><td>85.7</td><td>430</td><td>75.7</td></tr><tr><td>Differentiated (<italic>n</italic> = 601)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td> Well-moderately</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>449</td><td>79.3</td><td rowspan="2">&lt;<bold>0.001</bold></td></tr><tr><td> Poorly</td><td>35</td><td>100</td><td>28</td><td>100</td><td>117</td><td>20.7</td></tr><tr><td>Liver metastasis</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td> No</td><td>29</td><td>82.9</td><td>`15</td><td>53.6</td><td>132</td><td>23.1</td><td rowspan="2">&lt;<bold>0.001</bold></td></tr><tr><td> Yes</td><td>6</td><td>17.1</td><td>13</td><td>46.4</td><td>440</td><td>76.9</td></tr><tr><td>Lung metastasis</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td> No</td><td>29</td><td>82.9</td><td>22</td><td>78.6</td><td>184</td><td>32.2</td><td rowspan="2">&lt;<bold>0.001</bold></td></tr><tr><td> Yes</td><td>6</td><td>17.1</td><td>6</td><td>21.4</td><td>388</td><td>67.8</td></tr><tr><td>Peritoneal metastasis</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td> No</td><td>6</td><td>17.1</td><td>7</td><td>25.0</td><td>383</td><td>67.0</td><td rowspan="2">&lt;<bold>0.001</bold></td></tr><tr><td> Yes</td><td>29</td><td>82.9</td><td>21</td><td>75.0</td><td>189</td><td>33.0</td></tr><tr><td>MMR status (<italic>n</italic> = 472)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td> pMMR</td><td>29</td><td>87.9</td><td>19</td><td>90.5</td><td>404</td><td>95.1</td><td rowspan="2">0.10</td></tr><tr><td> dMMR</td><td>4</td><td>12.1</td><td>2</td><td>9.5</td><td>21</td><td>4.9</td></tr><tr><td>CIMP (<italic>n</italic> = 215)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td> CIMP-L/neg</td><td>2</td><td>66.7</td><td>5</td><td>71.4</td><td>175</td><td>75.1</td><td rowspan="2">–<sup>a</sup></td></tr><tr><td> CIMP-H</td><td>1</td><td>33.3</td><td>2</td><td>28.6</td><td>58</td><td>24.9</td></tr></tbody></table><table-wrap-foot><p>The Bold values are statistically significant</p><p>A <italic>p</italic>-value &lt; 0.05 indicates statistical significance</p><p><italic>SRCC</italic> signet ring cell colorectal cancer, <italic>AC with SC</italic> adenocarcinoma with signet ring cell component, <italic>AC</italic> adenocarcinoma</p><p>*<italic>p</italic>-value for SRCC compared with AC</p><p><sup>a</sup>No statistical analysis due to small sample size</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec11">
                <title>Molecular characteristics</title>
                <p id="Par16">Two hundred and six cases were tested with the 46-gene panel while 429 cases were tested with the 50-gene panel. Details relating to gene mutation frequencies in the SRCC, AC with SC component, and AC groups are shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>. Compared with the AC group, SRCC was commonly found with <italic>KRAS</italic> wild-type (wt) (OR: 7.7, 95% CI: 2.7–22.0; <italic>p</italic> &lt; 0.001), <italic>APC</italic> wt (OR: 26.8, 95% CI: 3.6–196.9; <italic>p</italic> = 0.001) and <italic>PIK3CA</italic> wt (OR: 6.7, 95% CI: 0.9–49.9; <italic>p</italic> = 0.06). No significant association was observed between SRCC and MSI, <italic>NRAS</italic>, <italic>BRAF</italic>, <italic>SMAD4</italic>, <italic>TP53</italic> or <italic>FBXW7</italic> status. No difference in gene mutation detection was noted between the two gene panels except in <italic>APC</italic> gene (46.6% in 50-gene panel vs 29.1% in 46-gene-panel, <italic>p</italic> &lt; 0.001) (Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref>). AC with SC component trended to have an intermediate prevalence of mutation in <italic>KRAS, APC and FBXW7</italic> between SRCC and AC group (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>AC molecular characteristics of adenocarcinoma, AC with SC adenocarcinoma with signet ring cell component and SRCC signet ring cell colorectal cancer</p></caption><graphic xlink:href="41416_2019_548_Fig1_HTML" id="d32e1776"/></fig></p>
              </sec>
              <sec id="Sec12">
                <title>Patient outcomes</title>
                <p id="Par17">The median follow-up time was 27 months. Univariate analysis by Kaplan–Meier survival analysis and log-rank test was performed using several factors, including age, primary tumour site, histological grade, histological type, <italic>KRAS, BRAF, PIK3CA</italic> and MSI status. Factors found to be significantly associated with worse OS were age 15–39 years (<italic>p</italic> = 0.002), right-sided tumour (<italic>p</italic> &lt; 0.001), poor differentiation (<italic>p</italic> &lt; 0.001), signet ring cell feature (<italic>p</italic> &lt; 0.001), <italic>KRAS</italic> mutation (<italic>p</italic> = 0.013), <italic>BRAF</italic> mutation (<italic>p</italic> &lt; 0.001) and pMMR (<italic>p</italic> = 0.016). Patients with SRCC tumours had significantly worse OS than patients with AC-mCRC (median OS: 16.4 months, 95% CI: 11.3–21.5 <italic>vs</italic>. median OS 47.2 months, 95% CI: 43.6-50.9, respectively; <italic>p</italic> &lt; 0.001) (Table <xref rid="Tab3" ref-type="table">3</xref>, Fig. <xref rid="Fig2" ref-type="fig">2</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Survival analyses<sup>a</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th colspan="4">Univariate analysis</th><th colspan="4">Multivariate analysis</th></tr><tr><th/><th><italic>n</italic></th><th>Median survival (mo)</th><th>95% CI</th><th><italic>p</italic>-value</th><th><italic>n</italic></th><th>HR</th><th>95% CI</th><th><italic>p</italic>-value</th></tr></thead><tbody><tr><td>Age (<italic>n</italic> = 662)</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>  15–39 years</td><td>70</td><td>36.8</td><td>27.0–46.6</td><td rowspan="3"><bold>0.002</bold></td><td>52</td><td>1.57</td><td>0.98–2.53</td><td>0.060</td></tr><tr><td>  40–49 years</td><td>152</td><td>41.2</td><td>32.4–49.9</td><td>123</td><td>1.34</td><td>0.97–1.86</td><td>0.077</td></tr><tr><td> ≥50 years</td><td>440</td><td>46.2</td><td>42.2–50.2</td><td>293</td><td>Ref.</td><td/><td/></tr><tr><td>Site (<italic>n</italic> = 656)</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>  Right-sided</td><td>242</td><td>35.7</td><td>30.6–40.8</td><td rowspan="2">&lt;<bold>0.001</bold></td><td>163</td><td>1.28</td><td rowspan="2">0.94–1.74</td><td rowspan="2">0.12</td></tr><tr><td>  Left-sided</td><td>414</td><td>48.8</td><td>44.9–52.7</td><td>305</td><td>Ref.</td></tr><tr><td>Differentiated (<italic>n</italic> = 656)</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>  Well-moderately</td><td>450</td><td>48.5</td><td>44.5–52.4</td><td rowspan="2">&lt;<bold>0.001</bold></td><td>331</td><td>Ref.</td><td/><td/></tr><tr><td>  Poorly</td><td>206</td><td>31.6</td><td>25.0–38.1</td><td>137</td><td>1.35</td><td>0.96–1.90</td><td>0.088</td></tr><tr><td><italic>KRAS</italic> (<italic>n</italic> = 661)</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>  Wild-type</td><td>358</td><td>48.2</td><td>43.1–53.4</td><td rowspan="2"><bold>0.013</bold></td><td>259</td><td>Ref.</td><td/><td/></tr><tr><td>  Mutant</td><td>303</td><td>40.7</td><td>35.1–46.4</td><td>209</td><td>1.51</td><td>1.17–1.95</td><td><bold>0.002</bold></td></tr><tr><td><italic>BRAF</italic> (<italic>n</italic> = 662)</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>  Wild-type</td><td>602</td><td>45.7</td><td>42.1–49.3</td><td rowspan="2">&lt;<bold>0.001</bold></td><td>425</td><td>Ref.</td><td/><td/></tr><tr><td>  Mutant</td><td>60</td><td>35.9</td><td>15.8–56.0</td><td>43</td><td>1.86</td><td>1.20–2.89</td><td><bold>0.005</bold></td></tr><tr><td><italic>PIK3CA</italic> (<italic>n</italic> = 658)</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>  Wild-type</td><td>560</td><td>45.6</td><td>41.6–49.6</td><td rowspan="2">0.111</td><td/><td/><td/><td/></tr><tr><td>  Mutant</td><td>98</td><td>42.4</td><td>33.6–51.1</td><td/><td/><td/><td/></tr><tr><td>MMR status (<italic>n</italic> = 498)</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>  Proficient</td><td>470</td><td>44.8</td><td>40.3–49.4</td><td rowspan="2"><bold>0.016</bold></td><td>442</td><td>Ref.</td><td>1.20–3.90</td><td rowspan="2"><bold>0.010</bold></td></tr><tr><td>  Deficient</td><td>28</td><td>35.9</td><td>8.5–63.4</td><td>26</td><td>2.17</td><td/></tr><tr><td>Histology (<italic>n</italic> = 633)</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>  AC</td><td>572</td><td>47.2</td><td>43.6–50.9</td><td rowspan="3">&lt;<bold>0.001</bold></td><td>416</td><td>Ref.</td><td/><td/></tr><tr><td>  AC with SC</td><td>26</td><td>19.3</td><td>10.7–27.8</td><td>19</td><td>2.63</td><td>1.30–5.33</td><td><bold>0.007</bold></td></tr><tr><td>  SRCC</td><td>35</td><td>16.4</td><td>11.3–21.5</td><td>33</td><td>3.11</td><td>1.73–5.60</td><td>&lt;<bold>0.001</bold></td></tr></tbody></table><table-wrap-foot><p>The Bold values are statistically significant</p><p>A <italic>p</italic>-value &lt; 0.05 indicates statistical significance</p><p><italic>CI</italic> confidence interval, <italic>HR</italic> hazard ratio, <italic>Ref.</italic> reference, <italic>SRCC</italic> signet ring cell colorectal cancer, <italic>AC with SC</italic> adenocarcinoma with signet ring cell component, <italic>AC</italic> adenocarcinoma</p><p><sup>a</sup>Only conducted among patients with available data</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Fig. 2</label><caption><p>Kaplan–Meier survival curve of CRC patients according to signet ring cell histology. Patients with SRCC had significantly worse OS (median overall survival [OS]: 16.4 mo, 95% confidence interval [CI]: 11.3–21.5) than patients with AC (median OS: 47.2 mo, 95% CI: 43.6–50.9) (<italic>p</italic> &lt; 0.001)</p></caption><graphic xlink:href="41416_2019_548_Fig2_HTML" id="d32e2521"/></fig></p>
                <p id="Par18">Multivariate Cox proportional hazard regression analysis revealed <italic>KRAS</italic> mutation (HR: 1.51, 95% CI: 1.17–1.95; <italic>p</italic> = 0.002), <italic>BRAF</italic> mutation (HR: 1.86, 95% CI: 1.20–2.89; <italic>p</italic> = 0.005) and pMMR (HR: 2.17, 95% CI: 1.20–3.90; <italic>p</italic> = 0.010) as independent predictors of worse outcome. After adjusting for all of these features, SRCC remained a significant prognostic factor for poor OS (HR: 3.11, 95% CI: 1.73–5.6; <italic>p</italic> &lt; 0.001) (Table <xref rid="Tab3" ref-type="table">3</xref>).</p>
              </sec>
            </sec>
            <sec id="Sec13" sec-type="discussion">
              <title>Discussion</title>
              <p id="Par19">This study identified the molecular characteristics of SRCC, which is a rare subtype of colorectal adenocarcinoma. We demonstrated associations between SRCC and <italic>KRASwt</italic>, <italic>PIK3CAwt</italic> and <italic>APCwt</italic>. This study also confirmed that SRCC is associated with young onset, right-sided tumour, peritoneal metastasis and poor outcome.</p>
              <p id="Par20">Adenocarcinoma is the most common histologic type of CRC, accounting for more than 90% of CRC cases. Mucinous adenocarcinoma (MAC) and SRCC are less commonly observed subtypes, with MAC accounting for 10% of cases, and SRCC accounting for 1% of cases.<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR21">21</xref>–<xref ref-type="bibr" rid="CR23">23</xref></sup> SRCC is defined by the presence of &gt;50% of tumour cells with intracytoplasmic mucin, whereas MAC is defined as carcinoma with &gt;50% of the tumour volume showing extracellular mucin.<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> Due to the rarity of this subtype and the difficulties associated with characterising it molecularly, genomic alteration data in SRCC are scarce. A summary of previously reported molecular alterations in SRCC are provided in Table <xref rid="Tab4" ref-type="table">4</xref>.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Clinical studies that investigating molecular features, MSI-H and CIMP-H in signet ring cell colorectal cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study</th><th>n</th><th>Stage</th><th>Histology</th><th><italic>KRAS</italic> (<italic>n</italic>, %)</th><th><italic>NRAS</italic> (<italic>n</italic>, %)</th><th><italic>BRAF</italic> (<italic>n</italic>, %)</th><th><italic>PIK3CA</italic> (<italic>n</italic>, %)</th><th><italic>FBXW7</italic> (<italic>n</italic>, %)</th><th><italic>APC</italic> (<italic>n</italic>, %)</th><th><italic>TP53</italic> (<italic>n</italic>, %)</th><th><italic>SMAD4</italic> (<italic>n</italic>, %)</th><th>MSI-H (<italic>n</italic>, %)</th><th>CIMP-H (<italic>n</italic>, %)</th></tr></thead><tbody><tr><td>Present study</td><td>35</td><td>IV</td><td>Confirmed ≥ 50% SC</td><td>4/35 (11.4%)</td><td>0/35 (0.0%)</td><td>3/35 (8.6%)</td><td>1/35 (2.9%)</td><td>1/35 (2.9%)</td><td>1/35 (2.9%)</td><td>21/35 (60.0%)</td><td>5/35 (14.3%)</td><td>4/33 (12.1%)</td><td>1/3 (33.3%)</td></tr><tr><td>Kawabata Y, 1999<sup><xref ref-type="bibr" rid="CR24">24</xref></sup></td><td>10</td><td>II–IV</td><td>Not confirmed</td><td>1/9 (11.0%)</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>3/10 (30.0%)</td><td>–</td></tr><tr><td>Kakar S, 2005<sup><xref ref-type="bibr" rid="CR4">4</xref></sup></td><td>45</td><td>I–IV</td><td>Confirmed ≥ 50% SC</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>12/45 (26.7%)</td><td>–</td></tr><tr><td>Ogino S, 2006<sup><xref ref-type="bibr" rid="CR25">25</xref></sup></td><td>9</td><td>NA</td><td>Confirmed ≥ 50% SC</td><td>0/8 (0.0%)</td><td>–</td><td>2/9 (22.0%)</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>2/8 (25.0%)</td><td>–</td></tr><tr><td>Kakar S, 2012<sup><xref ref-type="bibr" rid="CR17">17</xref></sup></td><td>33</td><td>I–IV</td><td>Confirmed ≥ 50% SC</td><td>16/30 (53.3%)</td><td>–</td><td>9/27 (33.3%)</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>8/33 (24.2%)</td><td>16/33 (48.5%)</td></tr><tr><td>Hartman DJ, 2013<sup><xref ref-type="bibr" rid="CR16">16</xref></sup></td><td>53</td><td>I–IV</td><td>Confirmed ≥ 50% SC</td><td>–</td><td>–</td><td>16/50 (32.0%)</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>23/53 (43.4%)</td><td>–</td></tr><tr><td>Inamura K, 2015<sup><xref ref-type="bibr" rid="CR15">15</xref></sup></td><td>20</td><td>I–IV</td><td>Confirmed ≥ 50% SC</td><td>1/17 (5.9%)</td><td>–</td><td>6/17 (35.3%)</td><td>1/16 (6.2%)</td><td>–</td><td>–</td><td>–</td><td>–</td><td>5/17 (29.4%)</td><td>5/17 (29.4%)</td></tr><tr><td>Nitsche U, 2016<sup><xref ref-type="bibr" rid="CR12">12</xref></sup></td><td>160</td><td>I–IV</td><td>Not confirmed</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>1/5 (20.0%)</td><td>–</td></tr><tr><td>Wei Q, 2016<sup><xref ref-type="bibr" rid="CR7">7</xref></sup></td><td>39</td><td>I–IV</td><td>Confirmed ≥ 50% SC</td><td>5/33 (15.2%)</td><td>–</td><td>1/33 (3.0%)</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Yalcin S, 2017<sup><xref ref-type="bibr" rid="CR28">28</xref></sup></td><td>9</td><td>II–IV</td><td>Confirmed ≥ 50% SC</td><td>–</td><td>–</td><td>4/9 (36.4%)</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Nam JY, 2018<sup><xref ref-type="bibr" rid="CR27">27</xref></sup></td><td>5</td><td>NA</td><td>Confirmed &gt; 50% SC</td><td>2/5 (40.0%)</td><td>0/5 (0.0%)</td><td>–</td><td>0/5 (0.0%)</td><td>1/5 (20.0%)</td><td>1/5 (20.0%)</td><td>2/5 (40.0%)</td><td>1/5 (20.0%)</td><td>–</td><td>–</td></tr></tbody></table></table-wrap></p>
              <p id="Par21">Our study identified a low rate of <italic>KRASmt</italic> (11.4%) in SRCC, which is comparable to the rates reported in many, but not all previous studies of SRCC.<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR25">25</xref>–<xref ref-type="bibr" rid="CR28">28</xref></sup> However, and importantly, the larger sample size in our study, our attention to confirmation of the histologic diagnosis, and use of NGS in a clinical lab should influence increased confidence in our results. The rate of MSI-H in this study was lower than previously reported in SRCC.<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup> This is likely due to the fact that our population was limited to stage IV disease, which normally has lower rate MSI-H compared to earlier stage disease.</p>
              <p id="Par22">Previous studies by Kakar S et al.<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> and Inamura K et al.<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> found <italic>BRAF V600E</italic> mutation and CIMP-positive status to be more common in SRCC, and proposed that SRCC might be related to the serrated pathway, based on the increased prevalence of <italic>BRAF V600E</italic>mt and CIIMP-positive status in a majority of serrated polyps.<sup><xref ref-type="bibr" rid="CR30">30</xref></sup> However, in metastatic disease, the findings of our study suggest that this association may not be as clear, and suggests the involvement of alternate carcinogenesis pathways.</p>
              <p id="Par23">Phosphatidylinositol-4,5-biphosphonate 3-kionase (<italic>PIK3CA</italic>) mutations have been reported in 10–20% of all CRC.<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> However, no detectable <italic>PIK3CA</italic> mutation was found in SRCC in this study, which is consistent with the findings of Inamura et al. who reported a prevalence of only 6.2% (1/16 cases) in SRCC.<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> Adenomatous polyposis coli (<italic>APC)</italic> mutations are the most commonly acquired mutation in sporadic colon cancer, and are considered the initial genetic alteration in CRC tumorigenesis.<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> Interestingly, our study found <italic>APCmt</italic> in only 3% of SRCC compared to 44% in AC group.</p>
              <p id="Par24">In the present study, we also reported the gene mutation frequencies in AC with SC component mCRC. Interestingly, the frequencies in most of the genes were similar to those observed in non-SC mCRC, while the frequencies in the other genes were varied between those observed in SRCC and those observed in non-SC mCRC (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). This could be influenced by mixed component of SRCC and conventional adenocarcinoma during the tissue selection process. It is, therefore, strongly encouraged to define the patient as either SRCC or AC with signet ring cell component.</p>
              <p id="Par25">When compared with conventional adenocarcinoma, SRCC has distinct clinicopathological characteristics. SRCC was reported to be predominately observed in younger onset group (especially in patients aged less than 40 years), and to be associated with right-sided tumour, advanced stage at presentation, and poor prognosis.<sup><xref ref-type="bibr" rid="CR8">8</xref>–<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR33">33</xref>–<xref ref-type="bibr" rid="CR35">35</xref></sup> The reported 5-year survival in the literature was 28.6–33%,<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup> but only 4.5% in stage IV disease.<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> Peritoneal carcinomatosis is the most common site of metastasis.<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> In our study, we found SRCC to be more commonly found in younger aged patients (especially age 15–39 years), right-sided tumour, poorly differentiated histology, more frequently with peritoneal metastasis over lung or liver metastasis and significantly inferior OS compared with non-SRCC tumours. We also found the worse prognosis of SC histology to be similar between SRCC and AC with SC component. We, therefore, conclude that any presence of signet ring cells of any proportion in CRC leads to poorer clinical outcomes.</p>
              <p id="Par26">This study has some mentionable limitations. First and consistent with the retrospective nature of this study, some patient data may have been missing or incomplete. Second, the data included in this study was from a single centre. Third, the sequencing panels that were used were limited to hotspot regions of several tumour suppressor genes. Therefore, the presence of other mutations outside of these regions cannot be excluded. Finally, the small number of included samples due to the rarity of SRCC may have given our study insufficient statistical power to identify all significant associations and differences. However, to the best of our knowledge, this is the largest study to evaluate the molecular profiles of SRCC. Further study to determine the key mechanism of tumour development is needed to improve treatments and patient outcomes.</p>
            </sec>
            <sec id="Sec14" sec-type="conclusion">
              <title>Conclusion</title>
              <p id="Par27">Colorectal SRCC has distinct molecular features, including low rates of <italic>KRAS</italic>, <italic>PIK3CA</italic> and <italic>APC</italic> mutations. Its unique clinical features and association with early age of disease onset necessitate further study to identify activation pathways and potential therapeutic targets.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary information</title>
              <sec id="Sec15">
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="41416_2019_548_MOESM1_ESM.docx">
                      <caption>
                        <p>Supplementary Figure and Tables</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p><bold>Publisher’s note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <sec>
              <title>Supplementary information</title>
              <p><bold>Supplementary information</bold> is available for this paper at 10.1038/s41416-019-0548-9.</p>
            </sec>
            <ack>
              <title>Acknowledgements</title>
              <p>I would like to express my very great appreciation to Dr Sarppasit Ariyapanya for his help in preparing the figures.</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Author contributions</title>
              <p>K.K.: conceptualisation, methodology, investigation, writing original draft, writing-reviewing and editing and visualisation. V.M., J.S.D., M.J.O., D.R.F., B.K.K, A.D., K.P.S.R., I.S., R.A.W., C.E and D.G.M.: writing-review and editing, and supervision. M.T., and S.H.: methodology, investigation, reviewing and editing. S.K.: conceptualisation, writing-reviewing and editing, and visualisation and supervision.</p>
            </notes>
            <notes id="FPar1" notes-type="COI-statement">
              <title>Competing interests</title>
              <p id="Par28">The authors declare no competing interests.</p>
            </notes>
            <notes id="FPar2">
              <title>Ethics approval and consent to participate</title>
              <p id="Par29">The protocol for this study was approved by The University of Texas MD Anderson Cancer Center Institutional Review Board. All patients provided written informed consent prior to sequencing of their tumours according to the institutional guideline. The study was performed in accordance with the Declaration of Helsinki.</p>
            </notes>
            <notes id="FPar3" notes-type="funding">
              <title>Funding</title>
              <p id="Par30">The University of Texas MD Anderson Cancer Center is supported in part by the National Institutes of Health through Cancer Center Support Grant P30CA016672 and R01CA187238.</p>
            </notes>
            <notes id="FPar4">
              <title>Data availability</title>
              <p id="Par31">The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</p>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ferlay</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Soerjomataram</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Dikshit</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Eser</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Mathers</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Rebelo</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012</article-title>
                  <source>Int. J. Cancer</source>
                  <year>2015</year>
                  <volume>136</volume>
                  <fpage>E359</fpage>
                  <lpage>E386</lpage>
                  <pub-id pub-id-type="doi">10.1002/ijc.29210</pub-id>
                  <pub-id pub-id-type="pmid">25220842</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nitsche</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Zimmermann</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Späth</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Müller</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Maak</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Schuster</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis</article-title>
                  <source>Ann. Surg.</source>
                  <year>2013</year>
                  <volume>258</volume>
                  <fpage>775</fpage>
                  <lpage>782</lpage>
                  <pub-id pub-id-type="doi">10.1097/SLA.0b013e3182a69f7e</pub-id>
                  <pub-id pub-id-type="pmid">23989057</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Anthony</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>George</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Rodriguez-Bigas</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Petrelli</surname>
                      <given-names>NJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Primary signet-ring cell carcinoma of the colon and rectum</article-title>
                  <source>Ann. Surg. Oncol.</source>
                  <year>1996</year>
                  <volume>3</volume>
                  <fpage>344</fpage>
                  <lpage>348</lpage>
                  <pub-id pub-id-type="doi">10.1007/BF02305663</pub-id>
                  <pub-id pub-id-type="pmid">8790846</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kakar</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Smyrk</surname>
                      <given-names>TC</given-names>
                    </name>
                  </person-group>
                  <article-title>Signet ring cell carcinoma of the colorectum: correlations between microsatellite instability, clinicopathologic features and survival</article-title>
                  <source>Mod. Pathol.</source>
                  <year>2005</year>
                  <volume>18</volume>
                  <fpage>244</fpage>
                  <lpage>249</lpage>
                  <pub-id pub-id-type="doi">10.1038/modpathol.3800298</pub-id>
                  <pub-id pub-id-type="pmid">15492759</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <mixed-citation publication-type="other">Hamilton S. R., Bosman F. T., Boffetta P., et al. Carcinoma of the colon and rectum. In: <italic>WHO Classification of Tumours of the Digestive System</italic> (eds Bosman F. T., Carneiro F., Hruban R. H., Theise N. D.) 134–146 (IARC Press, Lyon, 2010).</mixed-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Börger</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Gosens</surname>
                      <given-names>MJEM</given-names>
                    </name>
                    <name>
                      <surname>Jeuken</surname>
                      <given-names>JWM</given-names>
                    </name>
                    <name>
                      <surname>van Kempen</surname>
                      <given-names>LCLT</given-names>
                    </name>
                    <name>
                      <surname>van de Velde</surname>
                      <given-names>CJH</given-names>
                    </name>
                    <name>
                      <surname>van Krieken</surname>
                      <given-names>JHJM</given-names>
                    </name>
                    <name>
                      <surname>Nagtegaal</surname>
                      <given-names>ID</given-names>
                    </name>
                  </person-group>
                  <article-title>Signet ring cell differentiation in mucinous colorectal carcinoma</article-title>
                  <source>The Journal of Pathology</source>
                  <year>2007</year>
                  <volume>212</volume>
                  <issue>3</issue>
                  <fpage>278</fpage>
                  <lpage>286</lpage>
                  <pub-id pub-id-type="doi">10.1002/path.2181</pub-id>
                  <pub-id pub-id-type="pmid">17471475</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wei</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Gao</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Qi</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Clinicopathologic and molecular features of colorectal adenocarcinoma with signet-ring cell component</article-title>
                  <source>PLoS One</source>
                  <year>2016</year>
                  <volume>11</volume>
                  <fpage>e0156659</fpage>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0156659</pub-id>
                  <pub-id pub-id-type="pmid">27300552</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hyngstrom</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Hu</surname>
                      <given-names>CY</given-names>
                    </name>
                    <name>
                      <surname>Xing</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>You</surname>
                      <given-names>YN</given-names>
                    </name>
                    <name>
                      <surname>Feig</surname>
                      <given-names>BW</given-names>
                    </name>
                    <name>
                      <surname>Skibber</surname>
                      <given-names>JM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base</article-title>
                  <source>Ann. Surg. Oncol.</source>
                  <year>2012</year>
                  <volume>19</volume>
                  <fpage>2814</fpage>
                  <lpage>2821</lpage>
                  <pub-id pub-id-type="doi">10.1245/s10434-012-2321-7</pub-id>
                  <pub-id pub-id-type="pmid">22476818</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chew</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Yeo</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Ng</surname>
                      <given-names>ZP</given-names>
                    </name>
                    <name>
                      <surname>Lim</surname>
                      <given-names>KH</given-names>
                    </name>
                    <name>
                      <surname>Koh</surname>
                      <given-names>PK</given-names>
                    </name>
                    <name>
                      <surname>Ng</surname>
                      <given-names>KH</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Critical analysis of mucin and signet ring cell as prognostic factors in an Asian population of 2,764 sporadic colorectal cancers</article-title>
                  <source>Int J. Colorectal Dis.</source>
                  <year>2010</year>
                  <volume>25</volume>
                  <fpage>1221</fpage>
                  <lpage>1229</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00384-010-1033-3</pub-id>
                  <pub-id pub-id-type="pmid">20686777</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Barresi</surname>
                      <given-names>Valeria</given-names>
                    </name>
                    <name>
                      <surname>Reggiani Bonetti</surname>
                      <given-names>Luca</given-names>
                    </name>
                    <name>
                      <surname>Domati</surname>
                      <given-names>Federica</given-names>
                    </name>
                    <name>
                      <surname>Baron</surname>
                      <given-names>Luigi</given-names>
                    </name>
                  </person-group>
                  <article-title>Prognostic relevance of histopathological features in signet ring cell carcinoma of the colorectum</article-title>
                  <source>Virchows Archiv</source>
                  <year>2016</year>
                  <volume>469</volume>
                  <issue>3</issue>
                  <fpage>267</fpage>
                  <lpage>275</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00428-016-1983-0</pub-id>
                  <pub-id pub-id-type="pmid">27394431</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jung</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>JH</given-names>
                    </name>
                  </person-group>
                  <article-title>Prognostic impact of microsatellite instability in colorectal cancer presenting with mucinous, signet-ring, and poorly differentiated cells</article-title>
                  <source>Ann. Coloproctol.</source>
                  <year>2016</year>
                  <volume>32</volume>
                  <fpage>58</fpage>
                  <lpage>65</lpage>
                  <pub-id pub-id-type="doi">10.3393/ac.2016.32.2.58</pub-id>
                  <pub-id pub-id-type="pmid">27218096</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nitsche</surname>
                      <given-names>Ulrich</given-names>
                    </name>
                    <name>
                      <surname>Friess</surname>
                      <given-names>Helmut</given-names>
                    </name>
                    <name>
                      <surname>Agha</surname>
                      <given-names>Ayman</given-names>
                    </name>
                    <name>
                      <surname>Angele</surname>
                      <given-names>Martin</given-names>
                    </name>
                    <name>
                      <surname>Eckel</surname>
                      <given-names>Renate</given-names>
                    </name>
                    <name>
                      <surname>Heitland</surname>
                      <given-names>Wolf</given-names>
                    </name>
                    <name>
                      <surname>Jauch</surname>
                      <given-names>Karl-Walter</given-names>
                    </name>
                    <name>
                      <surname>Krenz</surname>
                      <given-names>Detlef</given-names>
                    </name>
                    <name>
                      <surname>Nüssler</surname>
                      <given-names>Natascha C.</given-names>
                    </name>
                    <name>
                      <surname>Rau</surname>
                      <given-names>Horst-Günter</given-names>
                    </name>
                    <name>
                      <surname>Ruppert</surname>
                      <given-names>Reinhard</given-names>
                    </name>
                    <name>
                      <surname>Schubert-Fritschle</surname>
                      <given-names>Gabriele</given-names>
                    </name>
                    <name>
                      <surname>Wilhelm</surname>
                      <given-names>Dirk</given-names>
                    </name>
                    <name>
                      <surname>Werner</surname>
                      <given-names>Jens</given-names>
                    </name>
                    <name>
                      <surname>Engel</surname>
                      <given-names>Jutta</given-names>
                    </name>
                  </person-group>
                  <article-title>Prognosis of mucinous and signet-ring cell colorectal cancer in a population-based cohort</article-title>
                  <source>Journal of Cancer Research and Clinical Oncology</source>
                  <year>2016</year>
                  <volume>142</volume>
                  <issue>11</issue>
                  <fpage>2357</fpage>
                  <lpage>2366</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00432-016-2224-2</pub-id>
                  <pub-id pub-id-type="pmid">27573386</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hugen</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Verhoeven</surname>
                      <given-names>RH</given-names>
                    </name>
                    <name>
                      <surname>Lemmens</surname>
                      <given-names>VE</given-names>
                    </name>
                    <name>
                      <surname>van Aart</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Elferink</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Radema</surname>
                      <given-names>SA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor</article-title>
                  <source>Int. J. Cancer</source>
                  <year>2015</year>
                  <volume>136</volume>
                  <fpage>333</fpage>
                  <lpage>339</lpage>
                  <pub-id pub-id-type="doi">10.1002/ijc.28981</pub-id>
                  <pub-id pub-id-type="pmid">24841868</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kermanshahi</surname>
                      <given-names>Taher Reza</given-names>
                    </name>
                    <name>
                      <surname>Magge</surname>
                      <given-names>Deepa</given-names>
                    </name>
                    <name>
                      <surname>Choudry</surname>
                      <given-names>Haroon</given-names>
                    </name>
                    <name>
                      <surname>Ramalingam</surname>
                      <given-names>Leksmi</given-names>
                    </name>
                    <name>
                      <surname>Zhu</surname>
                      <given-names>Benjamin</given-names>
                    </name>
                    <name>
                      <surname>Pingpank</surname>
                      <given-names>James</given-names>
                    </name>
                    <name>
                      <surname>Ahrendt</surname>
                      <given-names>Steven</given-names>
                    </name>
                    <name>
                      <surname>Holtzman</surname>
                      <given-names>Matthew</given-names>
                    </name>
                    <name>
                      <surname>Zeh</surname>
                      <given-names>Herbert</given-names>
                    </name>
                    <name>
                      <surname>Bartlett</surname>
                      <given-names>David</given-names>
                    </name>
                    <name>
                      <surname>Zureikat</surname>
                      <given-names>Amer</given-names>
                    </name>
                    <name>
                      <surname>Pai</surname>
                      <given-names>Reetesh K.</given-names>
                    </name>
                  </person-group>
                  <article-title>Mucinous and Signet Ring Cell Differentiation Affect Patterns of Metastasis in Colorectal Carcinoma and Influence Survival</article-title>
                  <source>International Journal of Surgical Pathology</source>
                  <year>2016</year>
                  <volume>25</volume>
                  <issue>2</issue>
                  <fpage>108</fpage>
                  <lpage>117</lpage>
                  <pub-id pub-id-type="doi">10.1177/1066896916664990</pub-id>
                  <pub-id pub-id-type="pmid">27571790</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Inamura</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Yamauchi</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Nishihara</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Mima</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Sukawa</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma</article-title>
                  <source>Ann. Surg. Oncol.</source>
                  <year>2015</year>
                  <volume>22</volume>
                  <fpage>1226</fpage>
                  <lpage>1235</lpage>
                  <pub-id pub-id-type="doi">10.1245/s10434-014-4159-7</pub-id>
                  <pub-id pub-id-type="pmid">25326395</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hartman</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Nikiforova</surname>
                      <given-names>MN</given-names>
                    </name>
                    <name>
                      <surname>Chang</surname>
                      <given-names>DT</given-names>
                    </name>
                    <name>
                      <surname>Chu</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Bahary</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Brand</surname>
                      <given-names>RE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Signet ring cell colorectal carcinoma: a distinct subset of mucin-poor microsatellite-stable signet ring cell carcinoma associated with dismal prognosis</article-title>
                  <source>Am. J. Surg. Pathol.</source>
                  <year>2013</year>
                  <volume>37</volume>
                  <fpage>969</fpage>
                  <lpage>977</lpage>
                  <pub-id pub-id-type="doi">10.1097/PAS.0b013e3182851e2b</pub-id>
                  <pub-id pub-id-type="pmid">23681075</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kakar</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Deng</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Smyrk</surname>
                      <given-names>TC</given-names>
                    </name>
                    <name>
                      <surname>Cun</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Sahai</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>YS</given-names>
                    </name>
                  </person-group>
                  <article-title>Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma</article-title>
                  <source>Mod. Pathol.</source>
                  <year>2012</year>
                  <volume>25</volume>
                  <fpage>1040</fpage>
                  <lpage>1047</lpage>
                  <pub-id pub-id-type="doi">10.1038/modpathol.2012.44</pub-id>
                  <pub-id pub-id-type="pmid">22522845</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Korphaisarn</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Morris</surname>
                      <given-names>VK</given-names>
                    </name>
                    <name>
                      <surname>Overman</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Fogelman</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Kee</surname>
                      <given-names>BK</given-names>
                    </name>
                    <name>
                      <surname>Raghav</surname>
                      <given-names>KPS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma</article-title>
                  <source>Oncotarget</source>
                  <year>2017</year>
                  <volume>8</volume>
                  <fpage>39268</fpage>
                  <lpage>39279</lpage>
                  <?supplied-pmid 28424412?>
                  <pub-id pub-id-type="pmid">28424412</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Singh</surname>
                      <given-names>RR</given-names>
                    </name>
                    <name>
                      <surname>Patel</surname>
                      <given-names>KP</given-names>
                    </name>
                    <name>
                      <surname>Routbort</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Reddy</surname>
                      <given-names>NG</given-names>
                    </name>
                    <name>
                      <surname>Barkoh</surname>
                      <given-names>BA</given-names>
                    </name>
                    <name>
                      <surname>Handal</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes</article-title>
                  <source>J. Mol. Diagn.</source>
                  <year>2013</year>
                  <volume>15</volume>
                  <fpage>607</fpage>
                  <lpage>622</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jmoldx.2013.05.003</pub-id>
                  <pub-id pub-id-type="pmid">23810757</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Korphaisarn</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Loree</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Nguyen</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Coulson</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Holla</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Litzenburger</surname>
                      <given-names>BC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature</article-title>
                  <source>Oncotarget</source>
                  <year>2017</year>
                  <volume>8</volume>
                  <fpage>57882</fpage>
                  <lpage>57888</lpage>
                  <?supplied-pmid 28915719?>
                  <pub-id pub-id-type="pmid">28915719</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kang</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>O’Connell</surname>
                      <given-names>JB</given-names>
                    </name>
                    <name>
                      <surname>Maggard</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Sack</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Ko</surname>
                      <given-names>CY</given-names>
                    </name>
                  </person-group>
                  <article-title>A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum</article-title>
                  <source>Dis. Colon Rectum</source>
                  <year>2005</year>
                  <volume>48</volume>
                  <fpage>1161</fpage>
                  <lpage>1168</lpage>
                  <pub-id pub-id-type="doi">10.1007/s10350-004-0932-1</pub-id>
                  <pub-id pub-id-type="pmid">15868237</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Verhulst</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Ferdinande</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Demetter</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Ceelen</surname>
                      <given-names>W</given-names>
                    </name>
                  </person-group>
                  <article-title>Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis</article-title>
                  <source>J. Clin. Pathol.</source>
                  <year>2012</year>
                  <volume>65</volume>
                  <fpage>381</fpage>
                  <lpage>388</lpage>
                  <pub-id pub-id-type="doi">10.1136/jclinpath-2011-200340</pub-id>
                  <pub-id pub-id-type="pmid">22259177</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gopalan</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Ho</surname>
                      <given-names>YH</given-names>
                    </name>
                    <name>
                      <surname>Lam</surname>
                      <given-names>AK</given-names>
                    </name>
                  </person-group>
                  <article-title>Signet-ring cell carcinoma of colorectum–current perspectives and molecular biology</article-title>
                  <source>Int J. Colorectal Dis.</source>
                  <year>2011</year>
                  <volume>26</volume>
                  <fpage>127</fpage>
                  <lpage>133</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00384-010-1037-z</pub-id>
                  <pub-id pub-id-type="pmid">20686774</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hamilton</surname>
                      <given-names>SR</given-names>
                    </name>
                  </person-group>
                  <article-title>BRAF mutation and microsatellite instability status in colonic and rectal carcinoma: context really does matter</article-title>
                  <source>J. Natl. Cancer Inst.</source>
                  <year>2013</year>
                  <volume>105</volume>
                  <fpage>1075</fpage>
                  <lpage>1077</lpage>
                  <pub-id pub-id-type="doi">10.1093/jnci/djt189</pub-id>
                  <pub-id pub-id-type="pmid">23878351</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kawabata</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Tomita</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Monden</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Ohue</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Ohnishi</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Sasaki</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Molecular characteristics of poorly differentiated adenocarcinoma and signet-ring-cell carcinoma of colorectum</article-title>
                  <source>Int. J. Cancer</source>
                  <year>1999</year>
                  <volume>84</volume>
                  <fpage>33</fpage>
                  <lpage>38</lpage>
                  <pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19990219)84:1&lt;33::AID-IJC7&gt;3.0.CO;2-Z</pub-id>
                  <pub-id pub-id-type="pmid">9988229</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ogino</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Brahmandam</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Cantor</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Namgyal</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Kawasaki</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Kirkner</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component</article-title>
                  <source>Mod. Pathol.</source>
                  <year>2006</year>
                  <volume>19</volume>
                  <fpage>59</fpage>
                  <lpage>68</lpage>
                  <pub-id pub-id-type="doi">10.1038/modpathol.3800482</pub-id>
                  <pub-id pub-id-type="pmid">16118624</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Imamura</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Morikawa</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Liao</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Lochhead</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Kuchiba</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Yamauchi</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers</article-title>
                  <source>Clin. Cancer Res.</source>
                  <year>2012</year>
                  <volume>18</volume>
                  <fpage>4753</fpage>
                  <lpage>4763</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-3210</pub-id>
                  <pub-id pub-id-type="pmid">22753589</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nam</surname>
                      <given-names>JY</given-names>
                    </name>
                    <name>
                      <surname>Oh</surname>
                      <given-names>BY</given-names>
                    </name>
                    <name>
                      <surname>Hong</surname>
                      <given-names>HK</given-names>
                    </name>
                    <name>
                      <surname>Bae</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>TW</given-names>
                    </name>
                    <name>
                      <surname>Ha</surname>
                      <given-names>SY</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Molecular characterization of colorectal signet-ring cell carcinoma using whole-exome and RNA sequencing</article-title>
                  <source>Transl. Oncol.</source>
                  <year>2018</year>
                  <volume>11</volume>
                  <fpage>836</fpage>
                  <lpage>844</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.tranon.2018.04.007</pub-id>
                  <pub-id pub-id-type="pmid">29747153</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yalcin</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Onguru</surname>
                      <given-names>O</given-names>
                    </name>
                  </person-group>
                  <article-title>BRAF mutation in colorectal carcinomas with signet ring cell component</article-title>
                  <source>Cancer Biol. Med.</source>
                  <year>2017</year>
                  <volume>14</volume>
                  <fpage>287</fpage>
                  <lpage>292</lpage>
                  <pub-id pub-id-type="doi">10.20892/j.issn.2095-3941.2017.0053</pub-id>
                  <pub-id pub-id-type="pmid">28884045</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kim</surname>
                      <given-names>YH</given-names>
                    </name>
                    <name>
                      <surname>Kakar</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Cun</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Deng</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>YS</given-names>
                    </name>
                  </person-group>
                  <article-title>Distinct CpG island methylation profiles and BRAF mutation status in serrated and adenomatous colorectal polyps</article-title>
                  <source>Int. J. Cancer</source>
                  <year>2008</year>
                  <volume>123</volume>
                  <fpage>2587</fpage>
                  <lpage>2593</lpage>
                  <pub-id pub-id-type="doi">10.1002/ijc.23840</pub-id>
                  <pub-id pub-id-type="pmid">18798261</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liao</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Morikawa</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Lochhead</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Imamura</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Kuchiba</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Yamauchi</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review</article-title>
                  <source>Clin. Cancer Res.</source>
                  <year>2012</year>
                  <volume>18</volume>
                  <fpage>2257</fpage>
                  <lpage>2268</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2410</pub-id>
                  <pub-id pub-id-type="pmid">22357840</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fodde</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Smits</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Clevers</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>APC, signal transduction and genetic instability in colorectal cancer</article-title>
                  <source>Nat. Rev. Cancer</source>
                  <year>2001</year>
                  <volume>1</volume>
                  <fpage>55</fpage>
                  <lpage>67</lpage>
                  <pub-id pub-id-type="doi">10.1038/35094067</pub-id>
                  <pub-id pub-id-type="pmid">11900252</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fu</surname>
                      <given-names>KI</given-names>
                    </name>
                    <name>
                      <surname>Sano</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Kato</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Saito</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Ochiai</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Fujimori</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Primary signet-ring cell carcinoma of the colon at early stage: a case report and a review of the literature</article-title>
                  <source>World J. Gastroenterol.</source>
                  <year>2006</year>
                  <volume>12</volume>
                  <fpage>3446</fpage>
                  <lpage>3449</lpage>
                  <pub-id pub-id-type="doi">10.3748/wjg.v12.i21.3446</pub-id>
                  <pub-id pub-id-type="pmid">16733868</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tung</surname>
                      <given-names>SY</given-names>
                    </name>
                    <name>
                      <surname>Wu</surname>
                      <given-names>CS</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>PC</given-names>
                    </name>
                  </person-group>
                  <article-title>Primary signet ring cell carcinoma of colorectum: an age- and sex-matched controlled study</article-title>
                  <source>Am. J. Gastroenterol.</source>
                  <year>1996</year>
                  <volume>91</volume>
                  <fpage>2195</fpage>
                  <lpage>2199</lpage>
                  <?supplied-pmid 8855747?>
                  <pub-id pub-id-type="pmid">8855747</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nozoe</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Anai</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Nasu</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Sugimachi</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>Clinicopathological characteristics of mucinous carcinoma of the colon and rectum</article-title>
                  <source>J. Surg. Oncol.</source>
                  <year>2000</year>
                  <volume>75</volume>
                  <fpage>103</fpage>
                  <lpage>107</lpage>
                  <pub-id pub-id-type="doi">10.1002/1096-9098(200010)75:2&lt;103::AID-JSO6&gt;3.0.CO;2-C</pub-id>
                  <pub-id pub-id-type="pmid">11064389</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
